Adjuvant nivolumab potential new standard-of-care for oesophageal cancer

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Oct 01 / Springer Healthcare

Adjuvant nivolumab potential new standard-of-care for oesophageal cancer

Oncology Gastrointestinal Cancer Cancer Immunotherapy ESMO-2020

Description

Ronan Kelly describes the main findings of the CheckMate 577 trial showing the disease-free survival benefit and tolerability of adjuvant nivolumab in individuals with resected oesophageal or gastro-oesophageal junction cancer.

Related Content

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.